Close
ACHEMA MIDDLE EAST 2026

Biologics And Regulations Propel Aseptic Fill-Finish Growth

Projected data suggests that the global expenditure on medications will reach $1.29 trillion by 2027(i). This surge in spending has led to a heightened...

Advancing Biopharmaceuticals With Novel Drug Modalities

The biopharmaceutical sector is undergoing a significant transformation in treating complex diseases, especially in oncology, driven by innovative drug approaches. This shift entails personalized...

Rising Analytics Use Shapes Pharmaceutical CDMO Industry

According to insights, the pharmaceutical CDMO market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.29% until 2028. This growth...

AMR Certification For Responsible Antibiotic Manufacturing

BSI, a UK standards body, introduced a new certification called the Minimized Risk of Antimicrobial Resistance (AMR) to promote responsible antibiotic manufacturing in the...

Pharma Adopts Digitalization For Improved Drug Manufacturing

A market report has gone on to show that to enhance efficiency as well as quality and also reduce costs when it comes to...

Sandoz, Evotec Launch AI-Driven Biosimilar Manufacturing

Sandoz, Just-Evotec Biologics have announced a collaboration to develop and manufacture multiple biosimilars. In the said agreement, Sandoz will get access to an AI-led...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...